Donna M. O'Neill
Technik-/Wissenschafts-/F&E-Leiter bei Aviv Healthcare Properties LP
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Steven Insoft | M | 60 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 11 Jahre |
Craig M. Bernfield | M | 63 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 19 Jahre |
Mark L. Wetzel | M | 66 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 3 Jahre |
Susan Lichtenstein | F | 67 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | - |
Norman R. Bobins | M | 81 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 3 Jahre |
Ben W. Perks | M | 81 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 9 Jahre |
Alan Edward Goldberg | M | 70 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 14 Jahre |
James Russell Triedman | M | 54 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 14 Jahre |
Sharon O'Keefe | F | 72 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 3 Jahre |
Mark McClellan | M | 60 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 3 Jahre |
James Roth | M | 66 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 3 Jahre |
Joshua J. Kochek | M | 46 | 16 Jahre | |
Steven R. Levin | M | 66 | 13 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jack J. Kogut | M | 77 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 15 Jahre |
James H. Lyman | M | 65 | 1 Jahre | |
Bob Demarest Lindsay | M | 68 | - | |
Michael Dees | M | 50 | - | |
John J. Hinds | M | - |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | - |
Mark Parrell | M | 57 | 2 Jahre | |
Zev Karkomi | M | 100 | - | |
Samuel H. Kovitz | M | 61 | 10 Jahre | |
Ari Ryan | M | 48 | - | |
Alan L. Heller | M | 70 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 3 Jahre |
Laurel A. Omert | M | 67 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 4 Jahre |
Edward C. Wood | M | 79 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 4 Jahre |
Steven E. Fleck | M | - |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 7 Jahre |
David J. Smith | M | 43 | 2 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 27 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Donna M. O'Neill
- Persönliches Netzwerk